FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Agneta Siegbahn

Research Profile

Chemicals & Drugs

Concepts & Ideas

Disorders

Physiology

Anatomy

Phenomena

Phosphorylation

Co-author Network

Publications

TOP 3
M Aberg; Agneta Siegbahn
Tissue factor non-coagulant signaling - molecular mechanisms and biological consequences with a focus on cell migration and apoptosis.
Christina Christersson; Matilda Johnell; Agneta Siegbahn
Evaluation of microparticles in whole blood by multicolour flow cytometry assay.
Axel Akerblom; Nils Asenblad; Richard C Becker; Andrzej Budaj; Marc J Claeys; Jay Horrow; Steen Husted; Hugo Katus; Agneta Siegbahn; Robert F Storey; Lars Wallentin; Stefan K James
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Agneta Siegbahn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: M Aberg; Agneta Siegbahn
Tissue factor non-coagulant signaling - molecular mechanisms and biological consequences with a focus on cell migration and apoptosis.
Journal of thrombosis and haemostasis : JTH 2013;11(5):817-25.
2013: Christina Christersson; Matilda Johnell; Agneta Siegbahn
Evaluation of microparticles in whole blood by multicolour flow cytometry assay.
Scandinavian journal of clinical and laboratory investigation 2013;73(3):229-39.
2012: Axel Akerblom; Nils Asenblad; Richard C Becker; Andrzej Budaj; Marc J Claeys; Jay Horrow; Steen Husted; Hugo Katus; Agneta Siegbahn; Robert F Storey; Lars Wallentin; Stefan K James
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
American heart journal 2012;164(5):728-34.
2012: Kai M Eggers; Tibor Kempf; Lars Lind; Johan Sundström; Lars Wallentin; Kai C Wollert; Agneta Siegbahn
Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects.
Scandinavian journal of clinical and laboratory investigation 2012;72(1):45-51.
2011: Christoph Varenhorst; Lars Wallentin; David Erlinge; Sasha Koul; Bo Lagerqvist; Agneta Siegbahn; Stefan James
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.
American heart journal 2011;162(2):363-71.
2011: Lars Lind; Agneta Siegbahn; Johan Sundström; Erik Ingelsson; Johan Arnlöv
A detailed cardiovascular characterization of obesity without the metabolic syndrome.
Arteriosclerosis, thrombosis, and vascular biology 2011;31(8):e27-34.
2011: M Aberg; Matilda Johnell; Malin Wickström; Agneta Siegbahn
Tissue Factor/ FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1).
Thrombosis research 2011;127(2):141-8.
2011: Spyridon Darmanis; Olle Ericsson; Simon Fredriksson; Mats G Gustafsson; Ivo Glynne Gut; Marta Gut; Simon Heath; Masood Kamali-Moghaddam; Rachel Yuan Nong; Agneta Siegbahn; Johan Vänelid; Lars Wallentin; Christofer Bäcklin; Ulf Landegren
ProteinSeq: high-performance proteomic analyses by proximity ligation and next generation sequencing.
PloS one 2011;6(9):e25583.
2011: Maria Ringvall; Åsa Thulin; Lei Zhang; Jessica Cedervall; Nobuko Tsuchida-Straeten; Willi Jahnen-Dechent; Agneta Siegbahn; Anna-Karin Olsson
Enhanced platelet activation mediates the accelerated angiogenic switch in mice lacking histidine-rich glycoprotein.
PloS one 2011;6(1):e14526.
2010: Christina Christersson; Matilda Johnell; Agneta Siegbahn
The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression.
Thrombosis research 2010;126(4):e327-33.
2010: Kai M Eggers; Tibor Kempf; Bo Lagerqvist; Bertil Lindahl; Sylvia Olofsson; Franziska Jantzen; Timo Peter; Tim Allhoff; Agneta Siegbahn; Per Venge; Kai C Wollert; Lars Wallentin
Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome.
Circulation. Cardiovascular genetics 2010;3(1):88-96.
2010: Spyros Darmanis; Rachel Yuan Nong; Maria Hammond; Jijuan Gu; Anders Alderborn; Johan Vänelid; Agneta Siegbahn; Sigrun Gustafsdottir; Olle Ericsson; Ulf Landegren; Masood Kamali-Moghaddam
Sensitive plasma protein analysis by microparticle-based proximity ligation assays.
Molecular & cellular proteomics : MCP 2010;9(2):327-35.
2009: Asa Thulin; Maria Ringvall; Anna Dimberg; Karin Kårehed; Timo Väisänen; Marja-Riitta Väisänen; Osama Hamad; Jian Wang; Rolf Bjerkvig; Bo Nilsson; Taina Pihlajaniemi; Helena Akerud; Kristian Pietras; Willi Jahnen-Dechent; Agneta Siegbahn; Anna-Karin Olsson
Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein.
Molecular cancer research : MCR 2009;7(11):1792-802.
2009: Ulrica Alström; Fredrik Granath; Jonas Oldgren; Elisabeth Ståhle; H Tydén; Agneta Siegbahn
Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery.
Thrombosis research 2009;124(5):572-7.
2009: Christoph Varenhorst; Stefan James; David Erlinge; John T Brandt; Oscar O Braun; Michael Man; Agneta Siegbahn; Joseph Walker; Lars Wallentin; Kenneth J Winters; Sandra L Close
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
European heart journal 2009;30(14):1744-52.
2009: Christoph Varenhorst; Stefan James; David Erlinge; Oscar O Braun; John T Brandt; Kenneth J Winters; Joseph A Jakubowski; Sylvia Olofsson; Lars Wallentin; Agneta Siegbahn
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
American heart journal 2009;157(3):562.e1-9.
2008: David Erlinge; Christoph Varenhorst; Oscar O Braun; Stefan James; Kenneth J Winters; Joseph A Jakubowski; John T Brandt; Atsuhiro Sugidachi; Agneta Siegbahn; Lars Wallentin
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
Journal of the American College of Cardiology 2008;52(24):1968-77.
2008: Mikael Aberg; Matilda Johnell; Malin Wickström; Anna Widunder; Agneta Siegbahn
Simvastatin reduces the production of prothrombotic prostasomes in human prostate cancer cells.
Thrombosis and haemostasis 2008;100(4):655-62.
2008: Oscar O Braun; Matilda Johnell; Christoph Varenhorst; Stefan James; John T Brandt; Joseph A Jakubowski; Kenneth J Winters; Lars Wallentin; David Erlinge; Agneta Siegbahn
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Thrombosis and haemostasis 2008;100(4):626-33.
2008: Lars Lind; Agneta Siegbahn; Johannes Hulthe; Anders Elmgren
C-reactive protein and e-selectin levels are related to vasodilation in resistance, but not conductance arteries in the elderly: the prospective investigation of the Vasculature in Uppsala Seniors (PIVUS) study.
Atherosclerosis 2008;199(1):129-37.
2008: C Christersson; Matilda Johnell; Agneta Siegbahn
Tissue factor and IL8 production by P-selectin-dependent platelet-monocyte aggregates in whole blood involves phosphorylation of Lyn and is inhibited by IL10.
Journal of thrombosis and haemostasis : JTH 2008;6(6):986-94.
2008: Anders Mälarstig; Per Eriksson; Anders Hamsten; Bertil Lindahl; Lars Wallentin; Agneta Siegbahn
Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome.
Heart (British Cardiac Society) 2008;94(6):724-9.
2008: Anders Mälarstig; Snaevar Sigurdsson; Per Eriksson; Gabrielle Paulsson-Berne; Ulf Hedin; Lars Wallentin; Agneta Siegbahn; Anders Hamsten; Ann-Christine Syvänen
Variants of the interferon regulatory factor 5 gene regulate expression of IRF5 mRNA in atherosclerotic tissue but are not associated with myocardial infarction.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(5):975-82.
2008: Jonas Oldgren; Nina Johnston; Agneta Siegbahn
Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
American heart journal 2008;155(3):493.e1-8.
2008: Lars Wallentin; Christoph Varenhorst; Stefan James; David Erlinge; Oscar O Braun; Joseph A Jakubowski; Atsuhiro Sugidachi; Kenneth J Winters; Agneta Siegbahn
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
European heart journal 2008;29(1):21-30.
2008: Mikael Aberg; Malin Wickström; Agneta Siegbahn
Simvastatin induces apoptosis in human breast cancer cells in a NFkappaB-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa.
Thrombosis research 2008;122(2):191-202.
2008: Agneta Siegbahn; Matilda Johnell; Anna Nordin; Mikael Aberg; Teet Velling
TF/FVIIa transactivate PDGFRbeta to regulate PDGF-BB-induced chemotaxis in different cell types: involvement of Src and PLC.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(1):135-41.
2007: Kai C Wollert; Tibor Kempf; Bo Lagerqvist; Bertil Lindahl; Sylvia Olofsson; Tim Allhoff; Timo Peter; Agneta Siegbahn; Per Venge; Helmut Drexler; Lars Wallentin
Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome.
Circulation 2007;116(14):1540-8.
2007: Christina Christersson; Jonas Oldgren; Anders Bylock; Agneta Siegbahn; Lars Wallentin
Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.
European heart journal 2007;28(6):692-8.
2007: Jonas Oldgren; Stefan K James; Agneta Siegbahn; Lars Wallentin
Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.
European heart journal 2007;28(6):699-704.
2007: Anders Mälarstig; Agneta Siegbahn
The intersubject variability of tissue factor mRNA production in human monocytes--relation with the toll-like receptor 4.
Thrombosis research 2007;120(3):407-13.
2007: Ulrica Alström; Hans Tydén; Jonas Oldgren; Agneta Siegbahn; Elisabeth Ståhle
The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment.
Thrombosis research 2007;120(3):353-9.
2007: Anders Mälarstig; Lars Wallentin; Agneta Siegbahn
Genetic variation in the interleukin-6 gene in relation to risk and outcomes in acute coronary syndrome.
Thrombosis research 2007;119(4):467-73.
2006: Nina Johnston; Tomas Jernberg; Bo Lagerqvist; Agneta Siegbahn; Lars Wallentin
Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease.
International journal of cardiology 2006;113(2):167-73.
2006: Stefan K James; Johan Lindbäck; Johanna Tilly; Agneta Siegbahn; Per Venge; Paul Armstrong; Robert M Califf; Maarten L Simoons; Lars Wallentin; Bertil Lindahl
Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy.
Journal of the American College of Cardiology 2006;48(6):1146-54.
2006: Anders Mälarstig; Bertil Lindahl; Lars Wallentin; Agneta Siegbahn
Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(7):1667-73.
2006: Tomas Jernberg; Christopher D Payne; Kenneth J Winters; Christelle Darstein; John T Brandt; Joseph A Jakubowski; Hideo Naganuma; Agneta Siegbahn; Lars Wallentin
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
European heart journal 2006;27(10):1166-73.
2006: Nina Johnston; Tomas Jernberg; Bo Lagerqvist; Agneta Siegbahn; Lars Wallentin
Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers.
The American journal of cardiology 2006;97(5):640-5.
2006: Helena Johansson; Masafumi Goto; Denis Dufrane; Agneta Siegbahn; Graciela Elgue; Pierre Gianello; Olle Korsgren; Bo Nilsson
Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006;6(2):305-12.
2006: Stefan K James; Bertil Lindahl; Jorik R Timmer; Jan Paul Ottervanger; Agneta Siegbahn; Mats Stridsberg; Paul Armstrong; Robert M Califf; Lars Wallentin; Maarten L Simoons
Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy).
The American journal of cardiology 2006;97(2):167-72.
2005: Anders Mälarstig; Taavo Tenno; Nina Johnston; Bo Lagerqvist; Tomas Axelsson; Ann-Christine Syvänen; Lars Wallentin; Agneta Siegbahn
Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(12):2667-72.
2005: Jonas Oldgren; C Fellenius; K Boman; Jan-Håkan Jansson; Tage Nilsson; Lars Wallentin; Agneta Siegbahn
Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.
Journal of internal medicine 2005;258(5):420-7.
2005: C Christersson; Jonas Oldgren; Anders Bylock; Lars Wallentin; Agneta Siegbahn
Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
Journal of thrombosis and haemostasis : JTH 2005;3(10):2245-53.
2005: Bo Lagerqvist; Erik Diderholm; Bertil Lindahl; S Husted; Fredrik Kontny; Elisabeth Ståhle; Eva Swahn; Per Venge; Agneta Siegbahn; Lars Wallentin
FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease.
Heart (British Cardiac Society) 2005;91(8):1047-52.
2005: Matilda Johnell; Rolf Larsson; Agneta Siegbahn
The influence of different heparin surface concentrations and antithrombin-binding capacity on inflammation and coagulation.
Biomaterials 2005;26(14):1731-9.
2005: Stefan K James; Jonas Oldgren; Johan Lindbäck; Nina Johnston; Agneta Siegbahn; Lars Wallentin
An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease.
American heart journal 2005;149(4):619-26.
2005: Agneta Siegbahn; Matilda Johnell; Brit Sorensen; Lars C Petersen; Carl-Henrik Heldin
Regulation of chemotaxis by the cytoplasmic domain of tissue factor.
Thrombosis and haemostasis 2005;93(1):27-34.
2004: Anna Schölin; Agneta Siegbahn; Lars Lind; Christian Berne; Göran Sundkvist; Erik Björk; F Anders Karlsson
CRP and IL-6 concentrations are associated with poor glycemic control despite preserved beta-cell function during the first year after diagnosis of type 1 diabetes.
Diabetes/metabolism research and reviews 2004;20(3):205-10.
2004: Jonas Oldgren; Agneta Siegbahn; Lars Grip; Rikard Linder; Kristian Thygesen; Lars Wallentin
Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
Thrombosis and haemostasis 2004;91(2):381-7.
2004: Stefan K James; Agneta Siegbahn; Paul Armstrong; Elliot S Barnathan; Robert M Califf; Maarten L Simoons; Lars Wallentin
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
American heart journal 2004;147(2):267-74.
2003: Tomas Jernberg; Bertil Lindahl; Agneta Siegbahn; Bertil Andren; Gunnar Frostfeldt; Bo Lagerqvist; Mats Stridsberg; Per Venge; Lars Wallentin
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease.
Journal of the American College of Cardiology 2003;42(11):1909-16.
2003: Taavo Tenno; Fredrik Oberg; Nigel Mackman; Kenneth Nilsson; Agneta Siegbahn
PML/RARalpha plays a role for basal activity and retinoid-induced repression of the tissue factor promoter in acute promyelocytic leukemia cells.
Thrombosis and haemostasis 2003;90(5):930-9.
2003: A Lignell; Agneta Siegbahn; M Stridsberg; Karlis Pauksen; Rolf Gedeborg; Jan Sjölin
Low utilisation of unactivated protein C in a patient with meningococcal septic shock and disseminated intravascular coagulation.
Acta anaesthesiologica Scandinavica 2003;47(7):897-900.
2003: Stefan K James; Bertil Lindahl; Agneta Siegbahn; Mats Stridsberg; Per Venge; Paul Armstrong; Elliot S Barnathan; Robert M Califf; Eric J Topol; Maarten L Simoons; Lars Wallentin
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.
Circulation 2003;108(3):275-81.
2003: Lars Wallentin; Lott Bergstrand; Mikael Dellborg; Carin Fellenius; Christopher B Granger; Bertil Lindahl; Lars Eric Lins; Tage Nilsson; Kenneth Pehrsson; Agneta Siegbahn; Eva Swahn
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
European heart journal 2003;24(10):897-908.
2003: Stefan K James; Paul Armstrong; Elliot S Barnathan; Robert M Califf; Bertil Lindahl; Agneta Siegbahn; Maarten L Simoons; Eric J Topol; Per Venge; Lars Wallentin
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy.
Journal of the American College of Cardiology 2003;41(6):916-24.
2003: Anders Mälarstig; Taavo Tenno; Surinder Jossan; Mikael Aberg; Agneta Siegbahn
A quantitative real-time PCR method for tissue factor mRNA.
Thrombosis research 2003;112(3):175-83.
2003: Jonas Oldgren; Lars Wallentin; Lars Grip; Rikard Linder; Bjarne Linde Nørgaard; Agneta Siegbahn
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease.
European heart journal 2003;24(1):86-93.
2002: Matilda Johnell; Graciela Elgue; S Thelin; R Larsson; Agneta Siegbahn
Cell adhesion and tissue factor upregulation in oxygenators used during coronary artery bypass grafting are modified by the Corline Heparin Surface.
Scandinavian cardiovascular journal : SCJ 2002;36(6):351-7.
2002: Eva Lindmark; Agneta Siegbahn
Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures: effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin.
Thrombosis research 2002;108(1):77-84.
2002: Matilda Johnell; Graciela Elgue; Rolf Larsson; Anders Larsson; Stefan Thelin; Agneta Siegbahn
Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface.
The Journal of thoracic and cardiovascular surgery 2002;124(2):321-32.
2002: Gunnar Frostfeldt; Gunnar Gustavsson; Bertil Lindahl; Anders Nygren; Agneta Siegbahn; Lars Wallentin
Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction.
Thrombosis research 2002;105(3):193-9.
2001: Eva Lindmark; Erik Diderholm; Lars Wallentin; Agneta Siegbahn
Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.
JAMA : the journal of the American Medical Association 2001;286(17):2107-13.
2001: Eva Lindmark; Lars Wallentin; Agneta Siegbahn
Blood cell activation, coagulation, and inflammation in men and women with coronary artery disease.
Thrombosis research 2001;103(3):249-59.
2001: Jonas Oldgren; Rikard Linder; Lars Grip; Agneta Siegbahn; Lars Wallentin
Coagulation activity and clinical outcome in unstable coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(6):1059-64.
2000: Agneta Siegbahn; Matilda Johnell; Charlotte Rorsman; M Ezban; Carl-Henrik Heldin; Lars Rönnstrand
Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis.
Blood 2000;96(10):3452-8.
2000: Bertil Lindahl; H Toss; Agneta Siegbahn; Per Venge; Lars Wallentin
Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
The New England journal of medicine 2000;343(16):1139-47.
2000: Eva Lindmark; Taavo Tenno; Agneta Siegbahn
Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(10):2322-8.
2000: Niels Erik Nielsen; Agneta Siegbahn; Eva Swahn
Markers of hypercoagulation and von Willebrand factor in postmenopausal women with unstable coronary artery disease. Discriminatory ability regarding unstable coronary artery disease and coronary atherosclerosis using receiver operating characteristics.
Journal of internal medicine 2000;248(2):151-8.
2000: Taavo Tenno; Johan Botling; Fredrik Oberg; S Jossan; Kenneth Nilsson; Agneta Siegbahn
The role of RAR and RXR activation in retinoid-induced tissue factor suppression.
Leukemia 2000;14(6):1105-11.
2000: Christian Olsson; Agneta Siegbahn; E Haldén; Bo Nilsson; Per Venge; Stefan Thelin
No benefit of reduced heparinization in thoracic aortic operation with heparin-coated bypass circuits.
The Annals of thoracic surgery 2000;69(3):743-9.
2000: Agneta Siegbahn
Cellular consequences upon factor VIIa binding to tissue factor.
Haemostasis 2000;30 Suppl 2():41-7.
2000: Christian Olsson; Agneta Siegbahn; A Henze; Bo Nilsson; Per Venge; P O Joachimsson; Stefan Thelin
Heparin-coated cardiopulmonary bypass circuits reduce circulating complement factors and interleukin-6 in paediatric heart surgery.
Scandinavian cardiovascular journal : SCJ 2000;34(1):33-40.
1999: Jonas Oldgren; Rikard Linder; Lars Grip; Agneta Siegbahn; Lars Wallentin
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
European heart journal 1999;20(22):1657-66.
1999: A Holmberg; D Bergqvist; Agneta Siegbahn
Coagulation and fibrinolysis after open infrarenal abdominal aortic aneurysm repair in a long-term perspective.
Thrombosis research 1999;96(2):99-105.
1999: Taavo Tenno; Fredrik Oberg; Kenneth Nilsson; Agneta Siegbahn
Induction of differentiation in U-937 and NB4 cells is associated with inhibition of tissue factor production.
European journal of haematology 1999;63(2):112-9.
1999: Lars Rönnstrand; Agneta Siegbahn; Charlotte Rorsman; Matilda Johnell; K Hansen; Carl-Henrik Heldin
Overactivation of phospholipase C-gamma1 renders platelet-derived growth factor beta-receptor-expressing cells independent of the phosphatidylinositol 3-kinase pathway for chemotaxis.
The Journal of biological chemistry 1999;274(31):22089-94.
1999: A Holmberg; Agneta Siegbahn; B Westman; David Bergqvist
Ischaemia and reperfusion during open abdominal aortic aneurysm surgery induce extensive thrombin generation and activity.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 1999;18(1):11-6.
1999: Rikard Linder; Jonas Oldgren; Nils Egberg; Lars Grip; G Larson; Agneta Siegbahn; Lars Wallentin
The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
European heart journal 1999;20(7):506-18.
1999: A Holmberg; David Bergqvist; B Westman; Agneta Siegbahn
Cytokine and fibrinogen response in patients undergoing open abdominal aortic aneurysm surgery.
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 1999;17(4):294-300.
1999: Gunnar Frostfeldt; G Ahlberg; G Gustafsson; G Helmius; Bertil Lindahl; Anders Nygren; Agneta Siegbahn; E Swahn; Per Venge; Lars Wallentin
Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).
Journal of the American College of Cardiology 1999;33(3):627-33.
1999: H Toss; Lars Wallentin; Agneta Siegbahn
Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease.
American heart journal 1999;137(1):72-8.
1998: Karina Ahlén; Ansgar Berg; fredrik stiger; Anders Tengholm; Agneta Siegbahn; Erik Gylfe; Rolf K Reed; Kristofer Rubin
Cell interactions with collagen matrices in vivo and in vitro depend on phosphatidylinositol 3-kinase and free cytoplasmic calcium.
Cell adhesion and communication 1998;5(6):461-73.
1998: Eva Lindmark; Taavo Tenno; J Chen; Agneta Siegbahn
IL-10 inhibits LPS-induced human monocyte tissue factor expression in whole blood.
British journal of haematology 1998;102(2):597-604.
1998: Peter Ridefelt; Agneta Siegbahn
Tyr1009 and Tyr1021 in the platelet-derived growth factor beta-receptor mediate agonist triggered calcium signalling.
Anticancer research 1998;18(3A):1819-25.
1998: H Toss; Judy Gnarpe; Håkan Gnarpe; Agneta Siegbahn; Bertil Lindahl; Lars Wallentin
Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease.
European heart journal 1998;19(4):570-7.
1998: M Ernofsson; FG Strekerud; H Toss; Ulrich Abildgaard; Lars Wallentin; Agneta Siegbahn
Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease.
Thrombosis and haemostasis 1998;79(3):491-4.
1998: Liisa Byberg; Agneta Siegbahn; Lars Berglund; Paul M McKeigue; Rikard Reneland; Hans Lithell
Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men.
Arteriosclerosis, thrombosis, and vascular biology 1998;18(2):258-64.
1997: H Toss; Bertil Lindahl; Agneta Siegbahn; Lars Wallentin
Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
Circulation 1997;96(12):4204-10.
1997: Taavo Tenno; Johan Botling; Fredrik Oberg; Kenneth Nilsson; Agneta Siegbahn
Tissue factor expression in human monocytic cell lines.
Thrombosis research 1997;88(2):215-28.
1997: R Hooshmand-Rad; Lena Claesson-Welsh; Stefan Wennström; K Yokote; Agneta Siegbahn; Carl-Henrik Heldin
Involvement of phosphatidylinositide 3'-kinase and Rac in platelet-derived growth factor-induced actin reorganization and chemotaxis.
Experimental cell research 1997;234(2):434-41.
1997: MW Johansson; M Patarroyo; Fredrik Oberg; Agneta Siegbahn; Kenneth Nilsson
Myeloperoxidase mediates cell adhesion via the alpha M beta 2 integrin (Mac-1, CD11b/CD18).
Journal of cell science 1997;110 ( Pt 9)():1133-9.
1997: M Ernofsson; S Thelin; Agneta Siegbahn
Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study.
The Journal of thoracic and cardiovascular surgery 1997;113(3):576-84.
1996: M Ernofsson; Taavo Tenno; Agneta Siegbahn
Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines.
British journal of haematology 1996;95(2):249-57.
1996: K Hansen; M Johnell; Agneta Siegbahn; Charlotte Rorsman; Ulla Engström; Christer Wernstedt; Carl-Henrik Heldin; Lars Rönnstrand
Mutation of a Src phosphorylation site in the PDGF beta-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis.
The EMBO journal 1996;15(19):5299-313.
1996: M Ernofsson; Agneta Siegbahn
Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor.
Thrombosis research 1996;83(4):307-20.
1996: Gunnar Nilsson; M Johnell; C H Hammer; H L Tiffany; Kenneth Nilsson; D D Metcalfe; Agneta Siegbahn; P M Murphy
C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(4):1693-8.
1996: Koutaro Yokote; S Mori; Agneta Siegbahn; Lars Rönnstrand; Christer Wernstedt; Carl-Henrik Heldin; Lena Claesson-Welsh
Structural determinants in the platelet-derived growth factor alpha-receptor implicated in modulation of chemotaxis.
The Journal of biological chemistry 1996;271(9):5101-11.
1995: M Ernofsson; S Thelin; Agneta Siegbahn
Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits.
Scandinavian journal of thoracic and cardiovascular surgery 1995;29(4):157-65.
1995: Peter Ridefelt; Koutaro Yokote; Lena Claesson-Welsh; Agneta Siegbahn
PDGF-BB triggered cytoplasmic calcium responses in cells with endogenous or stably transfected PDGF beta-receptors.
Growth factors (Chur, Switzerland) 1995;12(3):191-201.
1994: Johannes Waltenberger; Lena Claesson-Welsh; Agneta Siegbahn; M Shibuya; Carl-Henrik Heldin
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.
The Journal of biological chemistry 1994;269(43):26988-95.
1994: Gunnar Nilsson; J H Butterfield; Kenneth Nilsson; Agneta Siegbahn
Stem cell factor is a chemotactic factor for human mast cells.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(8):3717-23.
1994: E Rupp; Agneta Siegbahn; Lars Rönnstrand; Christer Wernstedt; Lena Claesson-Welsh; Carl-Henrik Heldin
A unique autophosphorylation site in the platelet-derived growth factor alpha receptor from a heterodimeric receptor complex.
European journal of biochemistry / FEBS 1994;225(1):29-41.
1994: S Wennström; Agneta Siegbahn; Koutaro Yokote; A K Arvidsson; Carl-Henrik Heldin; S Mori; Lena Claesson-Welsh
Membrane ruffling and chemotaxis transduced by the PDGF beta-receptor require the binding site for phosphatidylinositol 3' kinase.
Oncogene 1994;9(2):651-60.
1993: P Blume-Jensen; Agneta Siegbahn; S Stabel; Carl-Henrik Heldin; Lars Rönnstrand
Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C.
The EMBO journal 1993;12(11):4199-209.
1992: Flemming S Vassbotn; Arne Ostman; Agneta Siegbahn; Holm Holmsen; Carl-Henrik Heldin
Neomycin is a platelet-derived growth factor (PDGF) antagonist that allows discrimination of PDGF alpha- and beta-receptor signals in cells expressing both receptor types.
The Journal of biological chemistry 1992;267(22):15635-41.
1992: Carl-Henrik Heldin; Arne Ostman; A Eriksson; Agneta Siegbahn; Lena Claesson-Welsh; Bengt Westermark
Platelet-derived growth factor: isoform-specific signalling via heterodimeric or homodimeric receptor complexes.
Kidney international 1992;41(3):571-4.
1992: A Eriksson; Agneta Siegbahn; Bengt Westermark; Carl-Henrik Heldin; Lena Claesson-Welsh
PDGF alpha- and beta-receptors activate unique and common signal transduction pathways.
The EMBO journal 1992;11(2):543-50.
1991: P Blume-Jensen; Lena Claesson-Welsh; Agneta Siegbahn; K M Zsebo; Bengt Westermark; Carl-Henrik Heldin
Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis.
The EMBO journal 1991;10(13):4121-8.
1991: R Luostarinen; Agneta Siegbahn; Tom Saldeen
Effects of dietary supplementation with vitamin E on human neutrophil chemotaxis and generation of LTB4.
Upsala journal of medical sciences 1991;96(2):103-11.
1990: B Fellström; Agneta Siegbahn; G Liljenberg; O Haglund; R Wallin; G Tufveson; L Bagge
Primary haemostasis, plasmatic coagulation and fibrinolysis in renal transplantation.
Thrombosis research 1990;59(1):97-104.
1990: Agneta Siegbahn; A Hammacher; Bengt Westermark; Carl-Henrik Heldin
Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes.
The Journal of clinical investigation 1990;85(3):916-20.
1990: Bengt Westermark; Agneta Siegbahn; Carl-Henrik Heldin; Lena Claesson-Welsh
B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(1):128-32.
1989: Agneta Siegbahn; S Y-Hassan; J Boberg; H Bylund; H S Neerstrand; P Ostergaard; U Hedner
Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin. A dose finding study with LMWH-Novo.
Thrombosis research 1989;55(6):767-78.
1989: Agneta Siegbahn; V Odlind; U Hedner; Per Venge
Coagulation and fibrinolysis during the normal menstrual cycle.
Upsala journal of medical sciences 1989;94(2):137-52.
1988: Agneta Siegbahn; L Ruusuvaara
Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Thrombosis and haemostasis 1988;60(3):361-4.
1988: Monica Nistér; A Hammacher; Karin Mellström; Agneta Siegbahn; Lars Rönnstrand; Bengt Westermark; Carl-Henrik Heldin
A glioma-derived PDGF A chain homodimer has different functional activities from a PDGF AB heterodimer purified from human platelets.
Cell 1988;52(6):791-9.
1987: Agneta Siegbahn; R C Garcia; K Kishi; Kenneth Nilsson; Per Venge
Specific binding of B-CLL cell-derived chemokinetic inhibitory factor (CIF) to human polymorphonuclear leukocytes.
European journal of haematology 1987;39(2):172-9.